drugset / Trial / NCT00348881

Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants

NCT00348881

Phase 3 Completed 2133 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a study to compare the safety and immune response of a pentavalent DTaP-HB-PRP\~T combined vaccine with Tritanrix-HepB/Hib™, when both are given concomitantly with OPV at 6, 10, and 14 weeks of age.

Timeline

Start
2006-06
Primary completion
2007-10
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject DTaP-HB-PRP~T Vaccine 0.5 ml Intramuscular
Comparator Tritanrix-HepB/Hib Vaccine 0.5 ml Intramuscular
Background Oral Poliomyelitis Vaccine Vaccine Oral